Synergy CHC Corp. posted a net loss of $14.8M for Q4 2025, translating to a loss per share of $1.35 compared to the consensus estimate of $0.01 earnings. The healthcare company’s quarterly results marked a sharp reversal from Q4 2024, when it recorded EPS of $0.01.
Revenue totaled $6.1M for the quarter, down 40.8% from the $10.3M recorded in Q4 2024. The steep decline in both top and bottom line metrics signals significant headwinds for the company during the final three months of the year. Loss per share widened dramatically, down 13400.0% from the prior-year period.
Despite the challenging quarter, Wall Street maintains a relatively optimistic stance on Synergy CHC Corp., with analyst consensus standing at 5 buy, 1 hold, and 0 sell ratings. The quarter’s results represent a substantial setback for the company as it navigates operational challenges in the healthcare sector.
A detailed analysis of Synergy CHC Corp.’s quarter follows shortly on AlphaStreet.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.